Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

(2011) M. Reck et al.   ANNALS OF ONCOLOGY

Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

(2011) Susanna V. Ulahannan et al.   CANCER INVESTIGATION

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

(2011) Jonathan A. Ledermann et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance

(2011) Qing-feng Xiang et al.   CELLULAR ONCOLOGY

Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients

(2010) P. M. Ellis et al.   CLINICAL CANCER RESEARCH

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy

(2009) G. Sonpavde et al.   ANNALS OF ONCOLOGY

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

(2009) A. du Bois et al.   ANNALS OF ONCOLOGY

Phase II study of sunitinib in men with advanced prostate cancer

(2009) M. Dror Michaelson et al.   ANNALS OF ONCOLOGY

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

(2009) K. Mross et al.   CLINICAL CANCER RESEARCH

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer

(2008) S. Attia et al.   CLINICAL CANCER RESEARCH

Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study

(2008) Giuseppe Di Lorenzo et al.   EUROPEAN UROLOGY

Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer

(2008) Jean-Pascal Machiels et al.   JOURNAL OF CLINICAL ONCOLOGY

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer survival in five continents: a worldwide population-based study (CONCORD)

(2008) Michel P Coleman et al.   LANCET ONCOLOGY